Does micafungin treat Aspergillus?

Micafungin is a relatively broad-spectrum antifungal agent with in vitro activity against Candida and Aspergillus species, as well as the mycelial forms of dimorphic fungi.

How does micafungin work?

This medication is used to treat a variety of fungal infections. It is also used to prevent fungal infections in patients who are having a stem cell transplant. Micafungin belongs to a class of drugs known as echinocandins. It works by stopping the growth of fungi.

When do you use antifungal prophylaxis?

Antifungal prophylaxis is regularly used during treatment of patients with some cancers, as subgroups with high rates of invasive fungal infections are readily identified; for these patients, prophylaxis has been shown to be of value. High-risk liver transplant recipients also benefit from antifungal prophylaxis.

Is micafungin fungistatic?

Available data support its efficacy in the treatment of esophageal and systemic candidiasis. Against Aspergillus species, the drug is “fungistatic”; however, open-trial data have suggested that micafungin might be useful in the treatment of refractory aspergillosis.

Does posaconazole cover Aspergillus?

Posaconazole is an extended-spectrum triazole with in vitro activity against a wide range of medically important fungi, including Aspergillus species [10,11– 12]. Posaconazole is active in vivo in several models of experimental pulmonary, cerebral, and disseminated aspergillosis [13–17].

How long does it take for micafungin to work?

Cover the IV bag during your infusion to protect the medicine from light. Use the medicine within 24 hours after mixing. Micafungin must be given slowly through an IV infusion, and each injection can take at least 1 hour to complete.

Does micafungin cover Candida albicans?

Micafungin is an effective antifungal agent useful for the therapy of invasive candidiasis. Candida albicans is the most common cause of invasive candidiasis; however, infections due to non-C.

What do Echinocandins do?

Echinocandins are a new class of antifungals and are water-soluble cyclic lipopeptides (lipid connected to a peptide) that inhibit glucan synthase. They are used to treat invasive fungal infections and show good activity against amphotericin B-resistant and fluconazole-resistant Candida guilliermondii.

Does micafungin cause thrombocytopenia?

Side effects of Micafungin treatment include thrombotic thrombocytopenic purpura (TTP), a condition characterized by microangiopathic hemolytic anemia and thrombocytopenia with microvascular thrombosis [40].

What is micafungin made of?

Micafungin is a semi-synthetic echinocandin derived from a natural product of the fungus Coleophama empedri with potent antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for fungal cell wall synthesis.

How often is micafungin given?

Micafungin belongs to a class of drugs known as echinocandins. It works by stopping the growth of fungi. HOW TO USE: This medication is given by injection into a vein as directed by your doctor, usually once a day over 1 hour.

What is the role of micafungin in the treatment of aspergillosis?

Invasive aspergillosis is a major cause of morbidity and mortality in immunocompromised patients, particularly those with neutropenia and those undergoing bone marrow or stem cell transplants. Micafungin is an echinocandin antifungal drug with activity against all major Candida spp. Currently, micaf …

What is the efficacy of micafungin in the treatment of candidiasis?

Two studies have reported similar efficacy among members of this class in murine models of invasive fungal infections, including candidiasis and aspergillosis, despite the greater in vitro potency of anidulafungin and micafungin (Paderu et al 2007; Wiederhold et al 2007).

Micafungin, an echinocandin antifungal agent with a novel mechanism of action, inhibits beta-(1,3)-D-glucan synthase interfering with fungal cell wall synthesis. It shows excellent antifungal activity against a broad range of Candida spp., including azole-resistant strains, and Aspergillus spp. in in vitro and animal studies.

What are the pharmacokinetics of micafungin in pediatric patients?

The pharmacokinetics of micafungin have also been evaluated in pediatric patients. Micafungin was administered at doses ranging from 0.5 to 4 mg/kg/day in an open-label phase I study of patients with febrile neutropenia ranging from age 2 to 17 years (Seibel et al 2005). Similar to adults, Cmaxand AUC values increased in a linear fashion.